M
63.39
-2.15 (-3.28%)
| Previous Close | 65.54 |
| Open | 65.71 |
| Volume | 547,322 |
| Avg. Volume (3M) | 1,125,548 |
| Market Cap | 4,957,072,384 |
| Price / Sales | 80.70 |
| Price / Book | 5.89 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Operating Margin (TTM) | -285.94% |
| Diluted EPS (TTM) | -4.16 |
| Quarterly Revenue Growth (YOY) | 235.80% |
| Total Debt/Equity (MRQ) | 1.65% |
| Current Ratio (MRQ) | 5.86 |
| Operating Cash Flow (TTM) | -237.91 M |
| Levered Free Cash Flow (TTM) | -112.40 M |
| Return on Assets (TTM) | -30.61% |
| Return on Equity (TTM) | -58.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Merus N.V. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 2.33% |
| % Held by Institutions | 99.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lynx1 Capital Management Lp | 31 Mar 2025 | 1,568,841 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (BMO Capital, 73.53%) | Buy |
| Median | 103.00 (62.49%) | |
| Low | 96.00 (Needham, 51.44%) | Buy |
| Average | 103.00 (62.49%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 60.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 06 Aug 2025 | 96.00 (51.44%) | Buy | 65.54 |
| 23 May 2025 | 88.00 (38.82%) | Buy | 55.14 | |
| BMO Capital | 23 May 2025 | 110.00 (73.53%) | Buy | 55.14 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Aug 2025 | Announcement | Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Jun 2025 | Announcement | Merus N.V. Announces Pricing of Public Offering of Common Shares |
| 04 Jun 2025 | Announcement | Merus N.V. Announces Pricing of Public Offering of Common Shares |
| 03 Jun 2025 | Announcement | Merus N.V. Announces Proposed Public Offering of Common Shares |
| 03 Jun 2025 | Announcement | Merus N.V. Announces Proposed Public Offering of Common Shares |
| 22 May 2025 | Announcement | Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC |
| 22 May 2025 | Announcement | Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC |
| 15 May 2025 | Announcement | Merus Announces the Journal Publication of Petosemtamab Mechanism of Action |
| 15 May 2025 | Announcement | Merus Announces the Journal Publication of Petosemtamab Mechanism of Action |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |